Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 428

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

Open access
Azab, Abdel Kareem, Runnels, Judith M., Pitsillides, Costas, Moreau, Anne-Sophie, Azab, Feda, Leleu, Xavier, Jia, Xiaoying, Wright, Renee, Ospina, Beatriz, Carlson, Alicia L., Alt, Clemens, Burwick, Nicholas, Roccaro, Aldo M., Ngo, Hai T., Farag, Mena, Melhem, Molly R., Sacco, Antonio, Munshi, Nikhil C., Hideshima, Teru, Rollins, Barrett J., Anderson, Kenneth C., Kung, Andrew L., Lin, Charles P., Ghobrial, Irene M.·2009·Blood

Abstract

The interaction of multiple myeloma (MM) cells with their microenvironment in the bone marrow (BM) provides a protective environment and resistance to therapeutic agents. We hypothesized that disruption of the interaction of MM cells with their BM milieu would lead to their sensitization to therapeutic agents such as bortezomib, melphalan, doxorubicin, and dexamethasone. We report that the CXCR4 inhibitor AMD3100 induces disruption of the interaction of MM cells with the BM reflected by mobilization of MM cells into the circulation in vivo, with kinetics that differed from that of hematopoietic stem cells. AMD3100 enhanced sensitivity of MM cell to multiple therapeutic agents in vitro by disrupting adhesion of MM cells to bone marrow stromal cells (BMSCs). Moreover, AMD3100 increased mobilization of MM cells to the circulation in vivo, increased the ratio of apoptotic circulating MM cells, and enhanced the tumor reduction induced by bortezomib. Mechanistically, AMD3100 significantly inhibited Akt phosphorylation and enhanced poly(ADP-ribose) polymerase (PARP) cleavage as a result of bortezomib, in the presence of BMSCs in coculture. These experiments provide a proof of concept for the use of agents that disrupt interaction with the microenvironment for enhancement of efficacy of cytotoxic agents in cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2008-10-186668

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 42 references

Cited by

See all 428

Metadata

Authors
Azab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A.-S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A. L., Alt, C., Burwick, N., Roccaro, A. M., Ngo, H. T., Farag, M., Melhem, M. R., Sacco, A., Munshi, N. C., Hideshima, T., Rollins, B. J., Anderson, K. C., Kung, A. L., Lin, C. P., & Ghobrial, I. M.
Venue
Blood
Published
2009-04-30
Volume
113
Issue
18
Pages
4341-4351
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2051517030
Cited by
428
References
42
FWCI
22.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. https://app.cochat.ai/papers/10.1182/blood-2008-10-186668
The paper
Azab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A.-S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A. L., Alt, C., Burwick, N., Roccaro, A. M., Ngo, H. T., Farag, M., Melhem, M. R., Sacco, A., Munshi, N. C., Hideshima, T., . . . Ghobrial, I. M. (2009). CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. https://doi.org/10.1182/blood-2008-10-186668

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.